GB0027552D0 - Anti-tumor compounds - Google Patents

Anti-tumor compounds

Info

Publication number
GB0027552D0
GB0027552D0 GBGB0027552.9A GB0027552A GB0027552D0 GB 0027552 D0 GB0027552 D0 GB 0027552D0 GB 0027552 A GB0027552 A GB 0027552A GB 0027552 D0 GB0027552 D0 GB 0027552D0
Authority
GB
United Kingdom
Prior art keywords
tumor compounds
tumor
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0027552.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
BOEHRINGER INGELHEIM PHARMA
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BOEHRINGER INGELHEIM PHARMA, Boehringer Ingelheim Pharma GmbH and Co KG filed Critical BOEHRINGER INGELHEIM PHARMA
Priority to GBGB0027552.9A priority Critical patent/GB0027552D0/en
Publication of GB0027552D0 publication Critical patent/GB0027552D0/en
Priority to PCT/EP2001/012812 priority patent/WO2002038590A1/en
Priority to AU2002220684A priority patent/AU2002220684A1/en
Priority to UY27014A priority patent/UY27014A1/en
Priority to US10/036,224 priority patent/US20030232742A1/en
Priority to ARP010105240A priority patent/AR031316A1/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
GBGB0027552.9A 2000-11-10 2000-11-10 Anti-tumor compounds Ceased GB0027552D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB0027552.9A GB0027552D0 (en) 2000-11-10 2000-11-10 Anti-tumor compounds
PCT/EP2001/012812 WO2002038590A1 (en) 2000-11-10 2001-11-06 Fap-alpha-activated anti-tumor compounds
AU2002220684A AU2002220684A1 (en) 2000-11-10 2001-11-06 Fap-alpha-activated anti-tumor compounds
UY27014A UY27014A1 (en) 2000-11-10 2001-11-07 ANTITUMORAL COMPOUNDS ACTIVATED BY FAP II
US10/036,224 US20030232742A1 (en) 2000-11-10 2001-11-09 FAP-activated anti-tumor compounds
ARP010105240A AR031316A1 (en) 2000-11-10 2001-11-09 ANTITUMORAL COMPOUNDS ACTIVATED BY FAP II

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0027552.9A GB0027552D0 (en) 2000-11-10 2000-11-10 Anti-tumor compounds

Publications (1)

Publication Number Publication Date
GB0027552D0 true GB0027552D0 (en) 2000-12-27

Family

ID=9902983

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0027552.9A Ceased GB0027552D0 (en) 2000-11-10 2000-11-10 Anti-tumor compounds

Country Status (5)

Country Link
AR (1) AR031316A1 (en)
AU (1) AU2002220684A1 (en)
GB (1) GB0027552D0 (en)
UY (1) UY27014A1 (en)
WO (1) WO2002038590A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1963537A4 (en) * 2005-12-14 2009-11-11 Ludwig Inst For Cancer Res Ltd Method for diagnosing rheumatoid arthritis via assaying myofibroblast-like synoviocytes for fibroblast activation protein
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
EP2938360B1 (en) * 2012-12-28 2019-09-11 Cobiores NV Minimally toxic prodrugs
CN113967258A (en) * 2014-06-13 2022-01-25 塔夫茨大学信托人 FAP-activated therapeutics and uses related thereto
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
US11613785B2 (en) 2017-01-09 2023-03-28 Onkosxcel Therapeutics, Llc Predictive and diagnostic methods for prostate cancer
CA3203072A1 (en) 2020-12-22 2022-06-30 Andrea CASAZZA Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
EP0855910A4 (en) * 1995-10-18 2000-07-05 Merck & Co Inc Conjugates useful in the treatment of benign prostatic hyperplasia
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds

Also Published As

Publication number Publication date
WO2002038590A1 (en) 2002-05-16
UY27014A1 (en) 2002-07-31
AU2002220684A1 (en) 2002-05-21
AR031316A1 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
IL145798A0 (en) Fap-activated anti-tumor compounds
EP1349851A4 (en) Compounds
AU2405002A (en) Dehalogeno compounds
GB0019950D0 (en) Compounds
GB0027552D0 (en) Anti-tumor compounds
GB0027551D0 (en) Anti-tumor compounds
GB0027554D0 (en) Anti-tumor compounds
GB0015853D0 (en) Compounds
GB0014641D0 (en) Compounds
GB0005387D0 (en) Compounds
GB0005370D0 (en) Compounds
GB0031077D0 (en) Compounds
GB0023193D0 (en) Compounds
GB0021531D0 (en) Compounds
GB0004053D0 (en) Compounds
GB0020503D0 (en) Compounds
GB0019578D0 (en) Polysulphamated compounds
GB0018351D0 (en) Compounds
GB0018306D0 (en) Compounds
GB0015902D0 (en) Compounds
GB0015863D0 (en) Compounds
GB0009457D0 (en) Compounds
GB0015852D0 (en) Compounds
GB0014823D0 (en) Compounds
GB0014652D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)